Alterity Therapeutics Ltd
ASX:ATH
Alterity Therapeutics Ltd
Research & Development
Alterity Therapeutics Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alterity Therapeutics Ltd
ASX:ATH
|
Research & Development
-AU$14.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
|
Opthea Ltd
ASX:OPT
|
Research & Development
-$126.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-37%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Research & Development
-$34.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
CSL Ltd
ASX:CSL
|
Research & Development
-$1.4B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Research & Development
-AU$171.2m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Research & Development
-AU$70.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-38%
|
|
Alterity Therapeutics Ltd
Glance View
Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. The company is headquartered in Melbourne, Victoria and currently employs 11 full-time employees. The company went IPO on 2000-03-28. The firm focuses on developing disease modifying treatments for neurodegenerative conditions. The firm's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The firm also has a drug discovery platform generating chemical to intercede in disease processes.
See Also
What is Alterity Therapeutics Ltd's Research & Development?
Research & Development
-14.4m
AUD
Based on the financial report for Jun 30, 2025, Alterity Therapeutics Ltd's Research & Development amounts to -14.4m AUD.
What is Alterity Therapeutics Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-2%
Over the last year, the Research & Development growth was 23%. The average annual Research & Development growth rates for Alterity Therapeutics Ltd have been 1% over the past three years , -7% over the past five years , and -2% over the past ten years .
